A study to test how BI 456906 is taken up in the blood of people with and without kidney problems

2023-508557-13-00 Protocol 1404-0009 Human pharmacology (Phase I) - Other Ended

Start 8 May 2024 · End 23 Sep 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol 1404-0009

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 54
Countries 1
Sites 2

Renal impairment (mild, moderate and severe)

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
8 May 2024 → 23 Sep 2025
Decision date (initial)
2024-02-23
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-508557-13-00
WHO UTN
U1111-1298-3135

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Renal impairment (mild, moderate and severe)

VersionLevelCodeTermSystem organ class
22.1 PT 10062237 Renal impairment 100000004857
26.0 LLT 10088820 Clinical trial healthy volunteer 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 54 2
Rest of world 0

Investigational sites

Germany

2 sites · Ended
CRS Clinical Research Services Management GmbH
NA, Lornsenstrasse 7, Brunswik, Kiel
CRS Clinical Research Services Management GmbH
NA, Grenadierstrasse 1, Neckarstadt, Mannheim

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-05-08 2025-09-23 2024-05-15 2025-09-17

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-15 Germany Acceptable
2024-02-15
2024-02-23
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-20 Germany Acceptable
2024-07-09
2024-07-10
3 SUBSTANTIAL MODIFICATION SM-2 2024-10-29 Germany Acceptable
2024-11-14
2024-11-14
4 SUBSTANTIAL MODIFICATION SM-3 2024-12-20 Germany Acceptable
2025-01-14
2025-01-22
5 SUBSTANTIAL MODIFICATION SM-4 2025-05-20 Germany Acceptable
2025-06-04
2025-06-04